Pembrolizumab (MK-3475) versus platinum-based chemotherapy for PD-L1+non-small cell lung cancer (NSCLC): Randomized, open-label, phase 3 KEYNOTE-042 study

被引：0
|
作者：
Mok, T. [1 ]
Wu, Y. -L. [2 ,3 ]
Sadowski, S. [4 ]
Zhang, J. [5 ]
Rangwala, R. [4 ]
de Lima Lopes, G. [6 ,7 ]
机构：
[1] Chinese Univ Hong Kong, Clin Oncol, Hong Kong, Hong Kong, Peoples R China
[2] Guangdong Gen Hosp, Guangdong Lung Canc Inst, Guangzhou, Guangdong, Peoples R China
[3] Guangdong Acad Med Sci, Guangzhou, Guangdong, Peoples R China
[4] Merck & Co Inc, Clin Oncol, Kenilworth, NJ USA
[5] Merck & Co Inc, BARDS, Kenilworth, NJ USA
[6] Oncoclin Brasil Grp, Oncol, Sao Paulo, Brazil
[7] Johns Hopkins Univ, Sao Paulo, Brazil
来源：
ANNALS OF ONCOLOGY | 2015年 / 26卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
481TiP
引用
收藏
页码：147 / 147
页数：1
相关论文
共 50 条
  • [31] KEYNOTE-A86: Phase III, randomized, open-label study of first-line subcutaneous (SC) vs intravenous (IV) pembrolizumab with platinum doublet chemotherapy in metastatic squamous or nonsquamous non-small cell lung cancer (NSCLC)
    Halmos, B.
    Cobb, P.
    Johnson, M. L.
    Jain, L.
    Kim, S. J.
    Saraf, S.
    Lala, M.
    Kurata, T.
    ANNALS OF ONCOLOGY, 2021, 32 : S1456 - S1456
  • [32] Randomized open-label study of M7824 versus pembrolizumab as first-line (1L) treatment in patients with PD-L1 expressing advanced non-small cell lung cancer (NSCLC).
    Ahn, Myung-Ju
    Barlesi, Fabrice
    Felip, Enriqueta
    Garon, Edward B.
    Martin, Claudio Marcelo
    Mok, Tony S. K.
    Vokes, Everett E.
    Ojalvo, Laureen S.
    Koenig, Andre
    Dussault, Isabelle
    Paz-Ares, Luis G.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (08)
  • [33] Randomized open-label study of M7824 versus pembrolizumab as first-line (1L) treatment in patients with PD-L1 expressing advanced non-small cell lung cancer (NSCLC).
    Ahn, Myung-Ju
    Barlesi, Fabrice
    Felip, Enriqueta
    Garon, Edward B.
    Marcelo Martin, Claudio
    Mok, Tony S. K.
    Vokes, Everett E.
    Ojalvo, Laureen S.
    Koenig, Andre
    Dussault, Isabelle
    Paz-Ares, Luis G.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [34] KEYNOTE-177: First-line, open-label, randomized, phase III study of pembrolizumab (MK-3475) versus investigator-choice chemotherapy for mismatch repair deficient or microsatellite instability-high metastatic colorectal carcinoma.
    Diaz, Luis A.
    Le, Dung T.
    Yoshino, Takayuki
    Andre, Thierry
    Bendell, Johanna C.
    Zhang, Yinghua
    Lam, Baohoang
    Koshiji, Minori
    Jager, Dirk
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [35] Perioperative pembrolizumab plus platinum-based chemotherapy for resectable locally advanced non-small cell lung cancer: The phase III KEYNOTE-671 study
    Tsuboi, M.
    Luft, A.
    Ursol, G.
    Kato, T.
    Levchenko, E.
    Eigendorff, E.
    Berard, H.
    Zurawski, B.
    Demedts, I.
    Garassino, M. C.
    Yang, J.
    Makarious, K.
    Keller, S. M.
    Wakelee, H. A.
    ANNALS OF ONCOLOGY, 2020, 31 : S801 - S802
  • [36] Cilengitide combined with cetuximab and platinum-based chemotherapy as first-line treatment in advanced non-small-cell lung cancer (NSCLC) patients: results of an open-label, randomized, controlled phase II study (CERTO)
    Vansteenkiste, J.
    Barlesi, F.
    Waller, C. F.
    Bennouna, J.
    Gridelli, C.
    Goekkurt, E.
    Verhoeven, D.
    Szczesna, A.
    Feurer, M.
    Milanowski, J.
    Germonpre, P.
    Lena, H.
    Atanackovic, D.
    Krzakowski, M.
    Hicking, C.
    Straub, J.
    Picard, M.
    Schuette, W.
    O'Byrne, K.
    ANNALS OF ONCOLOGY, 2015, 26 (08) : 1734 - 1740
  • [37] Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 study
    Leigh, Natasha B.
    Hellmann, Matthew D.
    Hui, Rina
    Carcereny, Enric
    Felip, Enriqueta
    Ahn, Myung-Ju
    Eder, Joseph Paul
    Balmanoukian, Ani S.
    Aggarwal, Charu
    Horn, Leora
    Patnaik, Amita
    Gubens, Matthew
    Ramalingam, Suresh S.
    Lubiniecki, Gregory M.
    Zhang, Jin
    Piperdi, Bilal
    Garon, Edward B.
    LANCET RESPIRATORY MEDICINE, 2019, 7 (04): : 347 - 357
  • [38] Disease Response with the Addition of Platinum-Based Chemotherapy to Pembrolizumab after Progression on Pembrolizumab Monotherapy in PD-L1-Expressing Non-Small Cell Lung Cancer
    Garcia, Christine A.
    Dacic, Sanja
    Villaruz, Liza C.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (08) : E135 - E136
  • [39] Gefitinib (IRESSA) versus docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer pre-treated with platinum-based chemotherapy: a randomized, open-label Phase III study (INTEREST)
    Douillard, Jean-Yves
    Kim, Edward
    Hirsh, Vera
    Mok, Tony
    Socinski, Mark
    Gervais, Radj
    Wu, Yi-Long
    Li, Longyun
    Sellers, Mark
    Lowe, Elizabeth
    JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (08) : S305 - S306
  • [40] Pembrolizumab and platinum-based chemotherapy as first-line therapy for advanced non small-cell lung cancer: Phase 1 cohorts from the KEYNOTE-021 study
    Gadgeel, Shirish M.
    Stevenson, James P.
    Langer, Corey J.
    Gandhi, Leena
    Borghaei, Hossein
    Patnaik, Amita
    Villaruz, Liza C.
    Gubens, Matthew
    Hauke, Ralph
    Yang, James Chih-Hsin
    Sequist, Lecia V.
    Bachman, Robert
    Saraf, Sanatan
    Raftopoulos, Harry
    Papadimitrakopoulou, Vassiliki
    LUNG CANCER, 2018, 125 : 273 - 281
12345